Detect COVID-19 Binding Antibodies and Quantify COVID-19 Neutralizing Antibodies
A EUA Approved Panel now with 48-72 HR Reporting
The Neutralization Antibody (NAbs) Panel is an extremely useful, first-of-its-kind diagnostic test that facilitates the specific detection of IgG, IgM and quantitation of neutralizing antibodies (NAbs) against SARS-CoV-2. NAbs are a subset of IgG, IgM and IgA antibodies involved in key immune responses to shield cells from the virus, preventing infection propagation. Past COVID-19 infections can be detected from a qualitative binding IgG and IgM test.
The Neutralization Antibody Panel quickly and accurately detects and measures neutralization response in a sample against the SARS-CoV-2 virus.
Detecting IgG / IgA / IgM does NOT mean one has infection blocking NAbs!
cPass™ Neutralizing Antibody Panel
Vaccine Efficacy
Therapy Validation
cPass™ Key Benefits
Authorized for Usage via FDA EUA Approval Process
Sensitive & Specific
100% Positive & 100% Negative
Safe & Scalable
Easier and Readily Automatable
Quantifies
Measure and Track Levels Over Time
The cPass test is faster, easier, more scalable, and readily automatable compared to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT), and plaque reduction neutralization test (PRNT).
Reducing the Chromogenic Reaction
The panel contains two key components: the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD) and the human ACE2 receptor protein (hACE2).
The SARS-CoV-2 sVNT Kit is a blocking ELISA detection tool, which mimics the virus neutralization process. The test uses the interaction between viral protein-receptor protein to mimic the virus infection of a live cell, which is monitored by a chromogenic reaction. When there are neutralizing antibodies in the patient sera, they will block the specific protein-protein interaction and hence reducing the chromogenic reaction, mimicking the virus neutralization process.
